Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Glenmark Life Sciences Limited ( (IN:ALIVUS) ) is now available.
Alivus Life Sciences Limited has announced a schedule of meetings with analysts and institutional investors as part of its regulatory disclosure obligations. The company will hold one-on-one sessions with ICICI Direct via a virtual meeting on March 12, 2026, followed by in-person meetings in Mumbai with Green Lantern Capital and S Four Capital on March 16, 2026.
These interactions underscore Alivus Life Sciences’ efforts to maintain active engagement with the investment community and provide updates on its business to key market participants. The company also indicated that the schedule and mode of these meetings may change based on exigencies involving the investors, analysts, or the company itself.
More about Glenmark Life Sciences Limited
Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, operates in the life sciences and pharmaceutical sector. The company is listed in India and engages with equity markets through regular interactions with analysts and institutional investors, reflecting an active focus on investor relations and market transparency.
Average Trading Volume: 3,472
Technical Sentiment Signal: Sell
Current Market Cap: 111.5B INR
See more data about ALIVUS stock on TipRanks’ Stock Analysis page.